Method of treatment
AssigneeUniversity of Arkansas
InventorsJohn A. Thoma, Eid E. Haddad, Craig E. Whitfill, Alan P. Avakian
Life of this patent
Estimating the term…
Abstract
A method of producing active immunity against a bacterial or protozoal disease in a subject comprises administering to the subject a vaccine conjugate comprising a live bacteria or protozoa and a neutralizing factor bound to the live bacteria or protozoa. The neutralizing factor is selected from the group consisting of antibodies and antibody fragments. The live bacteria or protozoa is one capable of producing disease in the subject, and the antibody or antibody fragment is one capable of neutralizing the live bacteria or protozoa.
Claims31
A method of improving the safety of a live bacterial vaccine that produces protective immunity against a bacterial disease in a subject, said method comprising:
- administering to the subject a vaccine conjugate comprising a live pathogenic bacteria and a neutralizing factor bound to the live bacteria, the neutralizing factor selected from the group consisting of neutralizing antibodies and neutralizing antibody fragments which are capable of neutralizing the live bacteria;
- wherein the neutralizing factor is provided in the vaccine conjugate in an amount that temporarily neutralizes the live bacteria, so that
- the pathogenic effects of the live bacteria in the vaccine are delayed due to the addition of the neutralizing factor as compared with the pathogenic effects of the live bacteria in the absence of the neutralizing factor, and
- the live bacteria retains the ability to replicate and infect the subject and induce a protective immune response against a later challenge with the live bacteria in the subject.
An improved vaccine preparation for more safely producing protective immunity against a bacterial disease in a subject, said vaccine preparing comprising:
- a pharmaceutically acceptable formulation comprising a vaccine conjugate comprising a live pathogenic bacteria and a neutralizing factor bound to said live bacteria, said neutralizing factor selected from the group consisting of neutralizing antibodies and neutralizing antibody fragments which are capable of neutralizing the live bacteria;
- wherein said neutralizing factor is provided in said vaccine conjugate in an amount the temporarily neutralizes said live bacteria, so that
- the pathogenic effects of said live bacteria in the vaccine preparation are delayed due to the addition of the neutralizing factor as compared with the pathogenic effects of the live bacteria in the absence of said neutralizing factor, and said live bacteria retains the ability to replicate and infect a subject and induce a protective immune response against a later challenge with the live bacteria in said subject.
A method of improving the safety of a live mycoplasma vaccine that produces protective immunity against a mycoplasma in a subject, said method comprising:
- administering to the subject a vaccine conjugate comprising a live pathogenic mycoplasma and a neutralizing factor bound to the live mycoplasma, the neutralizing factor selected from the group consisting of neutralizing antibodies and neutralizing antibody fragments which are capable of neutralizing the live mycoplasma;
- wherein the neutralizing factor is provided in the vaccine conjugate in an amount that temporarily neutralizes the live mycoplasma, so that
- the pathogenic effects of the live mycoplasma in the vaccine are delayed due to the addition of the neutralizing factor as compared with the pathogenic effects of the live mycoplasma in the absence of the neutralizing factor, and
- the live mycoplasma retains the ability to replicate and infect the subject and induce a protective immune response against a later challenge with the live mycoplasma in the subject.
A method of improving the safety of a live bacterial vaccine that produces protective immunity against a bacterial disease in an avian subject, said method comprising:
- administering to the avian subject in ovo a vaccine conjugate comprising a live pathogenic bacteria and a neutralizing factor bound to the live bacteria, the neutralizing factor selected from the group consisting of neutralizing antibodies and neutralizing antibody fragments which are capable of neutralizing the live bacteria;
- wherein the neutralizing factor is provided in the vaccine conjugate in an amount that temporarily neutralizes the live bacteria, so that
- the pathogenic effects of the live bacteria in the vaccine are delayed due to the addition of the neutralizing factor as compared with the pathogenic effects of the live bacteria in the absence of the neutralizing factor, and
- the live bacteria retains the ability to replicate and infect the avian subject and induce a protective immune response against a later challenge with the live bacteria in the avian subject.
Dependencies are inferred from the claim text.